Baird Initiates Coverage On Denali Therapeutics with Outperform Rating, Announces Price Target of $31

Benzinga · 01/07 10:15
Baird analyst Joel Beatty initiates coverage on Denali Therapeutics (NASDAQ:DNLI) with a Outperform rating and announces Price Target of $31.